HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Glutamic Acid (Glutamate)

Subscribe to New Research on Glutamic Acid

A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.

Also Known As:

Glutamate; L-Glutamic Acid; D-Glutamate; L-Glutamate; Glutamic Acid, (D)-Isomer; D Glutamate; L Glutamate; L Glutamic Acid

Networked: 10581 relevant articles (335 outcomes, 1222 trials/studies) for this Drug, Comments

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins
- Amino Acids: 10517

Experts

1.	Lin, Mao-Tsun: 35 articles (08/2013 - 03/2002)
2.	Arendt-Nielsen, Lars: 26 articles (06/2014 - 01/2003)
3.	Meador-Woodruff, James H: 26 articles (04/2014 - 11/2003)
4.	Felipo, Vicente: 23 articles (02/2014 - 08/2002)
5.	Svensson, Peter: 22 articles (01/2015 - 01/2003)
6.	Haroutunian, Vahram: 20 articles (04/2014 - 07/2002)
7.	Teichberg, Vivian I: 20 articles (02/2014 - 09/2004)
8.	Slusher, Barbara S: 18 articles (04/2015 - 02/2002)
9.	Cairns, Brian E: 18 articles (01/2015 - 01/2003)
10.	Markou, Athina: 18 articles (10/2014 - 05/2004)

Related Diseases

1.	Ischemia 05/01/2010 - "Acupuncture (ACU) is known to be effective in ischemia treatment, and glutamate (GLU) excitotoxicity is an important factor in neuronal cell death. " 02/01/2010 - "Acupuncture has been known to be effective in ischemia, and glutamate excitotoxicity is an important factor for the neuronal cell death. " 08/27/1999 - "During the second half of 10-min ischemia, a significant increase in glutamate release was induced even in the dentate gyrus where CA4 neurons were eliminated; this increase was significantly suppressed by inhibiting proliferation of astrocytes. " 02/01/1998 - "In contrast, glutamate increased by sixfold during ischemia at 37 degrees C and remained significantly greater during reperfusion in the 34 degrees C and 37 degrees C groups. " 07/01/1997 - "Lesioned animals showed significantly greater numbers of surviving neurons and significantly lower ischemia-induced elevations of extracellular glutamate concentrations than nonlesioned animals. " Order ALL the reference details at left...
2.	Anoxia (Hypoxia) 04/01/1993 - "Glutamate uptake was relatively well preserved after a short hypoxic insult, while a marked decrease in glutamate uptake was observed after hypoxia of long duration. " 10/01/1991 - "The accumulation of glutamate in the external medium during anoxia was Ca2+ independent and insensitive to a significant reduction of the Ca(2+)-dependent release of the amino acid. " 01/01/2012 - "The protective effects were associated with reduction of glutamate and hypoxia-induced ROS production and alleviation of hypoxia-induced suppression of mitochondrial respiratory complex activities. " 01/01/2013 - "Here we show for the first time the direct correlation between the extent of differentiation (age) of astrocytes and the efficacy of EPO in balancing extracellular glutamate clearance and metabolism in an in-vitro model of hypoxia and Glu-induced astroglial injury. " 01/01/2013 - "It was experimentally ascertained that the most apparent antihypoxic action of study objects occurs in conditions of hypobaric hypoxia of acetylated derivative of glutamic acid considerably exceeds glutamic acid." Order ALL the reference details at left...
3.	Schizophrenia (Dementia Praecox) 06/01/2002 - "Activation of group II mGlu receptors (mGlu2 and mGlu3) decreases glutamate release from presynaptic nerve terminals, suggesting that group II mGlu receptor agonists may be beneficial in the treatment of schizophrenia. " 03/01/2015 - "The stimulation of metabotropic glutamate (mGlu) 2 receptor has been shown to be effective in a number of animal models of schizophrenia. " 01/01/2013 - "Both the stimulation of the metabotropic glutamate (mGlu) 2/3 receptor and the blockade of the mGlu1 receptor have been shown to be effective in a number of animal models of schizophrenia. " 11/01/2009 - "We describe here a coordinated brain imaging and animal models approach in which we have shown that the hippocampal CA1 region is a principal node in schizophrenia pathogenesis and have identified a novel treatment approach to the disorder based on inhibition of glutamate release. " 08/01/2007 - "Recent clinical studies reveal that selective agonists of group II metabotropic glutamate (mGlu) receptors have robust efficacy in treating positive and negative symptoms in patients with schizophrenia. " Order ALL the reference details at left...
4.	Seizures (Seizure) 01/25/2005 - "This sustained increase, which may contribute to the initiation and propagation of seizure activity, indicates impaired clearance of glutamate released by neurons. " 07/27/2001 - "Previous studies demonstrated that selected agonists for metabotropic glutamate group II and group III receptors can provide protection against seizures in adult animals. " 01/01/2013 - "This is the first AED with a specific action on glutamate-mediated excitatory neurotransmission to show evidence of efficacy and tolerability in reducing treatment-refractory partial-onset seizures in Phase III clinical trials. " 12/01/2005 - "Our study provides a novel mechanism, astrocytic release of glutamate, for seizure initiation." 07/01/2002 - "In vivo microdialysis studies show that seizure-associated glutamate release is doubled, and clearance is slowed. " Order ALL the reference details at left...
5.	Stroke (Strokes) 02/01/1988 - "These results suggest that this glutamate antagonist should be useful for the treatment of stroke." 06/01/2012 - "These studies show that the aging astrocyte may directly contribute to infarct severity by inefficient glutamate clearance and enhanced cytokine production and suggest a cellular target for improved stroke therapy among older females." 12/01/1995 - "The efficacy of these compounds in protecting central neurones from the effects of stroke may be indicative of the importance of the role that glutamate plays in this process." 03/01/2015 - "The aim of the present study was to investigate the relationship between acute ischemic stroke and glutamate levels and to determine the prognosis value of plasma glutamate levels to predict the functional outcome. " 12/01/2014 - "To extend these animal and cell-based studies to clinical patients, we measured the plasma levels of miR-107 and glutamate, and observed that both miR-107 and glutamate were elevated in patients with ischaemic stroke. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	N-Methylaspartate (NMDA)
2.	Aspartic Acid (Aspartate)
3.	Glutamine (L-Glutamine)
4.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
5.	Glycine (Aminoacetic Acid)
6.	gamma-Aminobutyric Acid (GABA)
7.	Dizocilpine Maleate (Dizocilpine)
8.	lamotrigine (Lamictal)
9.	Neurotransmitter Agents (Neurotransmitter)
10.	Oxaloacetate

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Oral Administration
3.	Injections
4.	Therapeutics
5.	Heterologous Transplantation (Xenotransplantation)

blog comments powered by Disqus

TREATMENT OPTIONS
for Ischemia,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 3699 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$24.95 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$490.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>